Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — IPO Roadshow (April 2021)
30 slides from Island Pharmaceuticals's IPO roadshow presentation, Apr 13, 2021
Slide 1: Solving Urgent Viral Disease Threats – IPO Roadshow
For personal use only SOLVING URGENT VIRAL DISEASE THREATS IPO Roadshow (ASX: ILA) April 2021 ISLAND PHARMACEUTICALS LIMITED 1 IPO ROADSHOW – APRIL 2021
Slide 2: Important Notice & Disclaimer
IMPORTANT NOTICE & DISCLAIMER This presentation has been prepared by Island Pharmaceuticals Limited financial, tax or other advice. Recipients of the presentation should guide only and should not be relied upon as an indication or guarantee For personal use only (ABN 641 183 842) (Company or Island
Slide 3: Contents
CONTENTS For personal use only 1. Introduction 4 2. Industry and market 8 3. Company overview 12 4. Key people 23 5. Details of the Offer 26 ISLAND PHARMACEUTICALS LIMITED 3 IPO ROADSHOW – APRIL 2021
Slide 4: Introduction
For personal use only INTRODUCTION ISLAND PHARMACEUTICALS LIMITED 4 IPO ROADSHOW – APRIL 2021
Slide 5: Island Snapshot
ISLAND SNAPSHOT BRINGING ITS PLATFORM IN A PILL TO MARKET For personal use only Island has repurposed ISLA-101, an Warming global antiviral oral drug to climates are treat mosquito-borne accelerating the viruses (eg dengue presence of mosquito- fever / Zika) and borne viruses that can intends to com
Slide 6: Key Strengths
KEY STRENGTHS For personal use only Initially targeting Drug repurposing Phase II Promising results Commercial Highly dengue diseases strategy ready asset to date upside experienced with unmet need team Targeting diseases, Lead compound, Repurposing can Results in Potential ‘platform Experienced Boa
Slide 7: Why Dengue Diseases?
WHY DENGUE DISEASES? SIGNIFICANT UNMET NEED FOR DISEASE WITH INCREASING INCIDENCE For personal use only Significant unmet need (3.9 billion people at risk) Increasing spread to US, EU and Australia ISLA-101 has both therapeutic and prophylactic potential Strong animal and human model results First c
Slide 8: Industry & Market
For personal use only INDUSTRY & MARKET ISLAND PHARMACEUTICALS LIMITED 8 IPO ROADSHOW – APRIL 2021
Slide 9: Mosquito Borne Diseases
MOSQUITO BORNE DISEASES MORE PATIENTS, HIGH COSTS, POTENTIALLY A LIFETIME OF ISSUES For personal use only Can result in life Primary target Dengue fever threatening conditions Mosquito-borne 390m flaviviruses Haemorrhagic fever West Nile virus Estimated global Shock syndrome cases per year (dengue f
Slide 10: Flaviviruses Becoming Global
FLAVIVIRUSES BECOMING GLOBAL WARMING GLOBAL CLIMATES ARE EXPANDING SPREAD BEYOND THE TROPICS For personal use only Flaviviruses are spreading outside the tropics: Japanese •1 Florida, US West Nile Encephalitis virus •2 Mediterranean, EU Tropic of West Nile 2 Cancer 7 6 •3 QLD, Australia 1 5 Zika Yel
Slide 11: Limited Available Solutions
LIMITED AVAILABLE SOLUTIONS HIGHLY PREVALENT DISEASES WITH UNMET MEDICAL NEED For personal use only Deformities in babies from mothers with Zika Dengue Zika Yellow Japanese West Nile fever Virus fever Encephalitis Viral diseases are a Worldwide 390 Up to n/a 130,000 70,000 leading cause of prevalenc
Slide 12: Company Overview
For personal use only COMPANY OVERVIEW ISLAND PHARMACEUTICALS LIMITED 12 IPO ROADSHOW – APRIL 2021
Slide 13: ISLA-101 Repurposed Drug
ISLA-101 REPURPOSED DRUG DRAMATICALLY REDUCES DEVELOPMENT TIME, RISK AND COST For personal use only Strong regulatory Speed to market ISLA-101, originally Demonstrated Capitalising on history and & early revenue a cancer drug as safe in humans millions spent acceptance potential Originally identifie
Slide 14: ISLA-101 Prevents Viral Replication
ISLA-101 PREVENTS VIRAL REPLICATION ISLA-101 INHIBITS PROPAGATION OF FLAVIVIRUSES For personal use only 1. Viral importation • To replicate, the virus needs to 3. Viral export hijack the nucleus of the host cell • Studies demonstrated ISLA-101 prevents this so prevents virus replication • Same mecha
Slide 15: ISLA-101 Broad Activity Evident
ISLA-101 BROAD ACTIVITY EVIDENT DEMONSTRATED ACTIVITY AGAINST FLAVIVIRUSES IN FRESH HUMAN CELLS For personal use only Dengue 1-4 • In in-vitro models using fresh human cells, ISLA-101 has demonstrated broad anti-viral activity Zika • In animal models, ISLA-101 is protective in dengue fever and Zika
Slide 16: Safety Profile of Drug Established
SAFETY PROFILE OF DRUG ESTABLISHED 45 HUMAN CLINICAL STUDIES OF ISLA-101 COMPLETED IN OTHER INDICATIONS For personal use only 4 2 Canada EU Verified as safe in 1 humans by multiple 1 Asia 39 regulators in other Middle US East clinical indications 3 Australia & NZ ISLAND PHARMACEUTICALS LIMITED 16 IP
Slide 17: Accelerated Time to Approval
ACCELERATED TIME TO APPROVAL LEVERAGING THE ESTABLISHED SAFETY PROFILE OF ISLA-101 For personal use only Completed Island repurposing timeline Significant near-term, value accretive news flow Millions of dollars Fast-track anticipated during and years saved on development development of ISLA- 101 Di
Slide 18: Phase II Challenge Study
PHASE II CHALLENGE STUDY AN EFFICIENTLY STRUCTURED TRIAL, LEVERAGING CRADA CONTROL DATA For personal use only Phase II trial protocol Up to 4 cohorts/4 arms Primary endpoint Administer Isla101 daily Inclusion • Healthy subjects • Assess the prophylactic effect of ISLA 101 on • Age 18-45 fever, clini
Slide 19: Clinical Development Program
CLINICAL DEVELOPMENT PROGRAM INITIAL FOCUS ON BRINGING A DENGUE FEVER DRUG TO MARKET For personal use only Activities to derisk Island’s Shortened timeframe for Investigational New Drug (IND) Phase II trials application Phase IIa Phase II/III New Drug Pre-IND IND Dengue fever Dengue fever Approval
Slide 20: Priority Review Voucher Eligibility
PRIORITY REVIEW VOUCHER ELIGIBILITY ISLA-101 INHIBITS THE STAGES AND PROTEINS OF FLAVIVIRUSES For personal use only Recent PRV acquisitions • ISLA-101 is eligible for Neglected Date Acquired by Value Tropical Disease designation for the treatment of dengue fever Q2 2018 Gilead US$81m Q4 2018 Eli Lil
Slide 21: Key Collaborations & Alliances
KEY COLLABORATIONS & ALLIANCES SUPPORTING FUTURE PIPELINE DEVELOPMENT For personal use only Research Collaboration Agreement to screen thousands of known molecules against host targets building upon the Fenretinide (ISLA-101) discovery sourced from these laboratories that the Company has licensed fo
Slide 22: Intellectual Property
INTELLECTUAL PROPERTY For personal use only • PCT/AU2014/050017, filed 16 April 2014 In-licensed • National stage applications underway/filed in Australia, Brazil, Canada, Singapore & US patents • Issued patents in Australia, Brazil and Singapore • Potential for new patents • Investigator Brochures
Slide 23: Key People
For personal use only KEY PEOPLE ISLAND PHARMACEUTICALS LIMITED 23 IPO ROADSHOW – APRIL 2021
Slide 24: Board of Directors
BOARD OF DIRECTORS For personal use only Dr. Paul MacLeman Dr. David Foster Dr. Anna Lavelle Mr. Al Hansen Dr. David Brookes Executive Chair CEO & Executive Director Non-Executive Director Non-Executive Director Non-Executive Director • Decades of experience across the • 20+ years experience in life
Slide 25: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD HEAVYWEIGHT ADVISORS WITH GLOBAL PEDIGREE For personal use only Assoc. Prof. Leigh Farrell Dr. Simon Tucker Prof. Stephen Thomas MD • Former Vice President of Business Development • Former Vice President of Research at Biota • International leadership role as Lead Principal
Slide 26: Details of the Offer
For personal use only DETAILS OF THE OFFER ISLAND PHARMACEUTICALS LIMITED 26 IPO ROADSHOW – APRIL 2021
Slide 27: Key Offer Information
KEY OFFER INFORMATION For personal use only Offer Summary* Offer Price per Share $0.25 Number of Shares available under the Offer 30,000,000 Gross proceeds from the Offer to the Company $7,500,000 Number of Shares on issue at IPO 50,968,466 Total number of Shares on issue on completion of the Offer
Slide 28: Use of Funds
USE OF FUNDS For personal use only Use of funds* A$ ('000) % of funds • Perform a Phase II clinical study Clinical, regulatory and on ISLA-101 implementation of proposed ISLA- $3,478,000 46.4% 101 development- Phase II study • Formulation development for Intellectual property, and research commercia
Slide 29: Important Dates
IMPORTANT DATES* For personal use only Prospectus lodgement Friday 26 February 2021 Offer period opens Monday 8 March 2021 Offer period closes Monday 29 March 2021 Settlement of the Offer and Allocation of Shares Friday 2 April 2021 Despatch of holder statements Tuesday 6 April 2021 Expected commenc
Slide 30: Island Pharmaceuticals Limited
For personal use only Island Pharmaceuticals Limited ACN 641 183 842 Authorised for release to the ASX by: Paul MacLeman Executive Chair paul@islapharma.com David Foster Chief Executive Officer & Executive Director david@islapharma.com www.islapharma.com Registered office: Suite 201, 697 Burke Rd, C